Moderna takes mRNA influenza candidate into Phase 3 trials - BioPharma-Reporter.com

Moderna has dosed the first participants in a Phase 3 study of the company’s seasonal influenza vaccine candidate, mRNA-1010.

The vaccine represents one of Modernas most advanced candidates outside of COVID-19 vaccines, and is one of several influenza vaccine vaccines being developed by the company. The company believes th… [+1503 chars]

full article...